+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc-siRNA Conjugates Drug Market - Global Forecast 2025-2030- Product Image
GalNAc-siRNA Conjugates Drug Market - Global Forecast 2025-2030- Product Image
Sale

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6121562
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

GalNAc-siRNA conjugate therapeutics are transforming targeted medicine by enabling precise hepatic delivery and durable gene silencing, opening new options for metabolic, oncological, and rare-disease management. This executive market analysis offers senior stakeholders a focused overview of commercial shifts, regulatory drivers, and competitive positioning within the evolving GalNAc-siRNA conjugate market.

Market Snapshot: GalNAc-siRNA Conjugate Therapeutics

The global GalNAc-siRNA conjugate therapeutics market is witnessing robust expansion, underpinned by rapid technological advancements in conjugation chemistry and delivery systems. Significant early clinical successes, combined with rising interest from investors and strategic partners, are reinforcing the segment’s growth trajectory. Pioneering improvements in ligand design—ensuring optimal receptor binding and endosomal release—are positioning these RNA silencing therapies at the forefront of metabolic, oncology, and rare-disease intervention. The market landscape further benefits from accelerating regulatory review pathways, enhanced collaboration between contract development organizations, and adaptive clinical designs that address both broad and specialist indications.

Scope & Segmentation

This report delivers comprehensive insights spanning technology, indication, end user, distribution, region, and application modalities. Key segmentation includes:

  • Indications: Hypercholesterolemia and type 2 diabetes in metabolic disorders; liver cancer in oncology; hATTR amyloidosis and hemophilia A in rare diseases.
  • End Users: Home healthcare, hospitals, research institutes, and specialty clinics reflecting diverse adoption environments and user requirements.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies, each presenting unique logistic and compliance demands.
  • Patient Age Groups: Adult and pediatric segments, with tailored safety and dosing considerations shaping clinical approaches.
  • Application Types: Prophylaxis and treatment modalities, supporting various clinical monitoring protocols and patient needs.
  • Regions: Americas—including United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, and Argentina. Europe, Middle East & Africa—including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland. Asia-Pacific—including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan.
  • Key Companies: Alnylam Pharmaceuticals, Inc.; Novartis AG; Arrowhead Pharmaceuticals, Inc.; Silence Therapeutics plc; Sirnaomics Co., Ltd.; Dicerna Pharmaceuticals, Inc.

Key Takeaways

  • GalNAc-siRNA conjugates leverage the strong affinity of GalNAc ligands to hepatocyte receptors, resulting in precise hepatic targeting and minimized systemic exposure for RNAi therapies.
  • Improved specificity and extended duration of gene silencing are fast-tracking platform adoption for both prevalent and rare disorders, while supporting rigorous safety standards across development pipelines.
  • Strategic industry alliances—spanning biotechs, academia, and contract manufacturers—are fostering a dynamic innovation ecosystem and enabling timely clinical scale-up.
  • AI-driven RNA design and advanced screening technologies are refining candidate prioritization, maximizing clinical success rates and optimizing R&D investments.
  • Emerging digital health platforms are complementing therapeutic regimens by enabling patient adherence monitoring and remote support, thus enhancing real-world evidence generation.
  • Market competitiveness is defined by integrated strategies encompassing ligand chemistry, manufacturing, clinical development, and value-based engagement with regulators and payers.

Tariff Impact on the GalNAc-siRNA Conjugate Therapeutics Market

Recent United States tariffs have increased the cost of pharmaceutical ingredients and critical manufacturing equipment, creating new financial challenges for GalNAc-siRNA developers. Companies are adjusting supply chains, seeking diversified sourcing, and adopting flexible manufacturing to mitigate impacts without compromising quality or compliance. Strategic engagement with payers is also prompting the revision of pricing and reimbursement approaches to ensure continued patient access and sustainable margins under evolving trade policies.

Methodology & Data Sources

The analysis integrates rigorous secondary research, including scientific literature, regulatory filings, pipeline data, and patents, with primary interviews involving key opinion leaders, executives, and policy specialists. Quantitative data were triangulated with market feedback and refined through peer expert review to ensure robust, actionable insights into the GalNAc-siRNA conjugate therapeutic environment.

Why This Report Matters

  • Informs C-suite and strategic leaders on paradigm-shifting trends, enabling more decisive investment and development decisions across the GalNAc-siRNA conjugate market.
  • Offers granular analysis of regulatory, policy, and competitive factors shaping commercial opportunities and potential barriers by region and indication.
  • Provides actionable guidance for aligning R&D, supply chain, and market access strategies with evolving payer, provider, and patient needs.

Conclusion

GalNAc-siRNA conjugate therapeutics are redefining the possibilities of precision medicine. Technology advancements, adaptive strategies, and focused stakeholder engagement collectively power growth opportunities for global market participants.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of GalNAc-siRNA pipelines targeting non-liver tissues via receptor diversification and advanced delivery technologies
5.2. Clinical data supporting safety profiles of long-acting subcutaneous GalNAc-siRNA therapies for chronic metabolic diseases
5.3. Emergence of next-generation GalNAc-siRNA platforms with enhanced endosomal escape and potency for low-dose administration
5.4. Strategic collaborations between biopharma companies and CDMOs to accelerate manufacture of GalNAc-siRNA conjugates at scale under cGMP
5.5. Regulatory guidance evolution for siRNA potency assays immunogenicity and impurity characterization in GalNAc-conjugated drugs
5.6. Advances in multiplexed siRNA conjugate therapies addressing polygenic liver disorders through combination design and dosing
5.7. Market penetration strategies for first-in-class GalNAc-siRNA therapies targeting rare hepatic disorders with orphan designations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. GalNAc-siRNA Conjugates Drug Market, by Indication
8.1. Introduction
8.2. Metabolic Disorders
8.2.1. Hypercholesterolemia
8.2.2. Type 2 Diabetes
8.3. Oncology
8.3.1. Liver Cancer
8.4. Rare Diseases
8.4.1. Hattr Amyloidosis
8.4.2. Hemophilia a
9. GalNAc-siRNA Conjugates Drug Market, by End User
9.1. Introduction
9.2. Home Healthcare
9.3. Hospitals
9.4. Research Institutes
9.5. Specialty Clinics
10. GalNAc-siRNA Conjugates Drug Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. GalNAc-siRNA Conjugates Drug Market, by Patient Age Group
11.1. Introduction
11.2. Adults
11.3. Pediatric
12. GalNAc-siRNA Conjugates Drug Market, by Application Type
12.1. Introduction
12.2. Prophylaxis
12.3. Treatment
13. Americas GalNAc-siRNA Conjugates Drug Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa GalNAc-siRNA Conjugates Drug Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific GalNAc-siRNA Conjugates Drug Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals, Inc.
16.3.2. Novartis AG
16.3.3. Arrowhead Pharmaceuticals, Inc.
16.3.4. Silence Therapeutics plc
16.3.5. Sirnaomics Co., Ltd.
16.3.6. Dicerna Pharmaceuticals, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GALNAC-SIRNA CONJUGATES DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GALNAC-SIRNA CONJUGATES DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GALNAC-SIRNA CONJUGATES DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GALNAC-SIRNA CONJUGATES DRUG MARKET: RESEARCHAI
FIGURE 26. GALNAC-SIRNA CONJUGATES DRUG MARKET: RESEARCHSTATISTICS
FIGURE 27. GALNAC-SIRNA CONJUGATES DRUG MARKET: RESEARCHCONTACTS
FIGURE 28. GALNAC-SIRNA CONJUGATES DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GALNAC-SIRNA CONJUGATES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 102. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 103. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 104. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 105. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 106. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 107. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 112. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 113. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 118. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 119. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 120. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 121. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 122. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 123. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 200. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 201. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 202. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 203. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 204. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 205. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 212. GERMANY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 213. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 216. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 217. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 218. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 219. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 220. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 221. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 226. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 227. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 245. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 248. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 249. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 250. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 251. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 252. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 253. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 258. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 259. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 260. ITALY GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 261. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 264. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 265. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 266. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 267. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 268. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 269. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 274. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 275. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 276. SPAIN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA GALNAC-S

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this GalNAc-siRNA Conjugates Drug market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG
  • Arrowhead Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Sirnaomics Co., Ltd.
  • Dicerna Pharmaceuticals, Inc.

Related Reports

GalNAc-siRNA Conjugates Market - Global Forecast 2025-2030 - Product Image

GalNAc-siRNA Conjugates Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
GalNac Conjugates Market - Global Forecast 2025-2030 - Product Image

GalNac Conjugates Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From
RNAi Technology - Global Strategic Business Report - Product Image

RNAi Technology - Global Strategic Business Report

  • Report
  • 138 Pages
  • Global
From
RNA Interference- Pipeline Insight, 2025 - Product Image

RNA Interference- Pipeline Insight, 2025

  • Drug Pipelines
  • 204 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.